Your session is about to expire
← Back to Search
Mirdametinib for Breast Cancer
Study Summary
This trial is testing if mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations.
- MEK1 Gene Mutation
- Breast Cancer
- MEK2 Gene Mutation
- Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 & 3 trial • 12 Patients • NCT02116803Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Arm 1, Part 1 - mirdametinib in combination with fulvestrant
- Group 2: Arm 1, Part 2 - mirdametinib in combination with fulvestrant
- Group 3: Arm 2, Part 1 - mirdametinib as single agent
- Group 4: Arm 2, Part 2 - mirdametinib as single agent
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other research papers that mention Mirdametinib?
"Mirdametinib was first studied in the year 2004 at Lowell General Hospital. To date there are a total of 89 completed clinical trials with 140 more currently underway. There is significant research being conducted out of Harrison, New york."
Is this study also taking place in other hospitals throughout Canada?
"There are 6 locations where this clinical trial is being conducted; these include Harrison, Commack and New york. If you decide to participate in this study, the investigators will work with you to select a site that is close to your home to minimize travel burden."
Are volunteers being sought for this clinical trial at the moment?
"The information available on clinicaltrials.gov supports that this trial is ongoing and looking for new participants. This particular study was first publicized on September 14th, 2021 with the most recent update being from September 13th, 2022. They are aiming to have 150 people enrolled from 6 different locations."
How many men and women are enrolled in this research project?
"That is correct, the clinicaltrials.gov website does show that this trial is open for recruitment. The listing shows that the study was first posted on September 14th, 2021 and was last updated on September 13th, 2022. They are looking for a total of 150 participants across 6 different sites."
What are the primary indications for Mirdametinib?
"Mirdametinib, while commonly used to treat endocrine conditions, can also be effective in treating other diseases such as breast cancer and those with a pik3ca gene mutation."
Share this study with friends
Copy Link
Messenger